Lead program

ONT01: Phase 1/2-stage, selective, small molecule integrin αMβ2 (CD11b) agonist for the treatment of lupus nephritis and focal segmental glomerulosclerosis (FSGS).

ONT01 addresses clinically-validated target with novel, differentiated mechanism — mitigating immune cell activation and recruitment/infiltration.

Previous clinical study of ONT01 demonstrates favorable safety and PK, while mechanism and preclinical data support therapeutic potential in kidney disease.